Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,784 total articles

Kaltura Puts the AI CEO Into Production With Ron Yekutiel’s Digital Twin, Using the Same Agentic Avatar Tech It Offers Enterprises

Kaltura Puts the AI CEO Into Production With Ron Yekutiel’s Digital Twin, Using the Same Agentic Avatar Tech It Offers Enterprises

Kaltura’s CEO Ron Yekutiel is actively using a multilingual, AI-powered digital twin based on the company's Agentic Avatar technology to deliver personalized video communications to employees and customers. This innovation improves communication efficiency and engagement by extending the CEO’s presence digitally across global offices and customers,…

SunPower Prices $41 Million Convertible Debt

SunPower Prices $41 Million Convertible Debt

SunPower Inc., a U.S.-based solar technology and services company, announced it has secured $41 million by issuing Convertible Senior Secured Notes with a 10% coupon and a 45% conversion premium. The funds will be used for working capital and to pay down approximately $40 million in existing debt through exchanges and conversions. The offering targ…

Kestra Showcases Accelerated Innovation at HRS 2026

Kestra Showcases Accelerated Innovation at HRS 2026

Kestra Medical Technologies is showcasing its Cardiac Recovery System platform, featuring the ASSURE wearable cardiac defibrillator, at the Heart Rhythm Society 2026 meeting. The company announced FDA approval of an algorithm update that improves patient protection using real-world data. Kestra continues to lead innovations in wearable cardiac medi…

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Healthcare Inc. announced its PSX-001 program aligns with a recent White House Executive Order aimed at accelerating the approval and availability of psychedelic treatments for serious mental illnesses. The company highlighted strong Phase 2 clinical trial results for PSX-001, its oral synthetic psilocybin therapeutic targeting Generalized…

Axe Compute Secures $260 million, Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment

Axe Compute Secures $260 million, Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment

Axe Compute Inc. announced a significant 36-month enterprise contract valued at approximately $260 million to deliver a dedicated cluster of 2,304 NVIDIA B300 GPUs and AI-focused high-speed storage at a Tier 3 US data center. This largest engagement in the company's history will support large-scale AI model training, fine-tuning, and inference task…

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Arcutis Biotherapeutics announced that ZORYVE® (roflumilast) cream has received a strong recommendation with high certainty of clinical evidence in the American Academy of Dermatology's first-ever guidelines for pediatric atopic dermatitis treatment. The guidelines endorse ZORYVE cream for children aged 2 years and older, highlighting its efficacy,…

Preferred Bank Reports First Quarter Results

Preferred Bank Reports First Quarter Results

Preferred Bank reported net income of $31.1 million ($2.53 per diluted share) for Q1 2026, a slight increase year-over-year but a decrease compared to the prior quarter. The results were impacted by a reversal of interest income due to a large loan relationship placed on nonaccrual status, rate cuts by the Federal Reserve, and lower noninterest inc…

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

Corbus Pharmaceuticals announced that updated clinical data for CRB-701, a next-generation Nectin-4 antibody-drug conjugate for oncology indications, will be presented at ASCO 2026. The data includes efficacy and safety in head and neck squamous cell carcinoma (HNSCC) and cervical cancer patients. The company plans to start a registrational study i…

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep Limited announces that a clinical abstract on its immunotherapy drug eftilagimod alfa has been accepted for poster presentation at the ASCO 2026 Annual Meeting. The data highlights the drug’s ability to activate lymphocytes rapidly and sustain immune response, with markers correlating to improved overall survival in metastatic cancer patien…

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Humacyte, Inc., a Nasdaq-listed biotechnology company specializing in bioengineered human tissues, has appointed Jim Mercadante as Chief Commercial Officer. With over 25 years of healthcare commercial experience, Mercadante will lead the expansion of Symvess, the company's first FDA-approved acellular tissue engineered vessel (ATEV), currently mark…

LiveOne (Nasdaq: LVO) Eliminates $15M+ Short-Term Liabilities, Delivering $13M+ in Cash Savings; Expands Stock Conversion Program to $15M+ at $7.50 per Share, with $8M Completed

LiveOne (Nasdaq: LVO) Eliminates $15M+ Short-Term Liabilities, Delivering $13M+ in Cash Savings; Expands Stock Conversion Program to $15M+ at $7.50 per Share, with $8M Completed

LiveOne (Nasdaq: LVO) announced strategic financial milestones including elimination of $15 million+ short-term liabilities, resulting in over $13 million in cash savings. The company also expanded its stock conversion program to over $15 million at $7.50 per share, with $8 million already completed, enhancing financial stability and supporting lon…

Las Vegas Metropolitan Police Signs Five-Year WrapReality™ Contract Renewal with WRAP® to Advance Immersive Training and Non-Lethal Response™ Preparedness

Las Vegas Metropolitan Police Signs Five-Year WrapReality™ Contract Renewal with WRAP® to Advance Immersive Training and Non-Lethal Response™ Preparedness

Wrap Technologies, Inc. announced a five-year contract renewal with the Las Vegas Metropolitan Police Department for continued deployment and support of its WrapReality immersive virtual reality training platform. This strategic renewal highlights the police department's endorsement of the platform's value in enhancing officer decision-making, de-e…

Enphase Energy Expands VPP Capabilities in Australia with Evergen

Enphase Energy Expands VPP Capabilities in Australia with Evergen

Enphase Energy announced an integration between its IQ Batteries and Evergen's advanced virtual power plant (VPP) orchestration platform, enhancing Australian homeowners' ability to optimize battery use, participate in grid-support programs, and benefit from various state and federal incentives. This collaboration aims to accelerate battery adoptio…

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

OPKO Health’s subsidiary, ModeX Therapeutics, has begun dosing patients in a Phase 1 clinical trial for MDX2003, a first-in-class tetraspecific T-cell engager antibody designed to treat relapsed or refractory B-cell lymphoma. MDX2003 targets two tumor antigens (CD19 and CD20) along with T-cell activators (CD3 and CD28) to enhance the immune system’…

The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform

The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform

The Beauty Health Company announced a corporate rebrand to SkinHealth Systems Inc. with the aim of becoming a clinically driven, science-backed medical aesthetics company. The company will continue trading under the ticker SKIN and focus on growing its skin health ecosystem anchored by its flagship Hydrafacial device along with complementary offeri…

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals has appointed Laurie Stelzer as the new Chair of its Board, succeeding Dr. Rich Heyman, effective after the 2026 Annual Meeting. This leadership transition coincides with the continuation of the PYNNACLE Phase 2 clinical trial of rezatapopt for TP53 Y220C mutated advanced solid tumors, with a planned NDA submission in early 2027…

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

Madrigal Pharmaceuticals announced it will release its first-quarter 2026 financial results on May 6, 2026, before the US financial market opens. The company will host a live webcast to discuss the financial and operating results. Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), including the …